Title: ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic ...

Aligos Therapeutics has a one year low of $6.76 and a one year high of $46.80. The stock has a market capitalization of $43.65 million, a price-to-earnings ratio of -0.54 and a beta of 2.52.

16:07 EDT Aligos Therapeutics (ALGS) files to sell 6.25M shares of common stock for holders Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed ...

Aligos Therapeutics (ALGS) announced positive data from three oral presentations at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver, APASL, 2025, being held ...

Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases. The company is dedicated to ...

SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The latest price target for Aligos Therapeutics (NASDAQ:ALGS) was reported by HC Wainwright & Co. on March 31, 2025. The analyst firm set a price target for $70.00 expecting ALGS to rise to within ...

SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics ...